JenaValve announced today that it began patient enrollment in the ARTIST study evaluating its Trilogy heart valve system.

The study isn’t intended to sway clinical decision-making, but to make doctors aware of the impact of their choices.

JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, today announced that patient enrollment has begun in the ARTIST study, an RCT evaluating ...

This procedure may also be recommended for patients who have aortic valve disease or other conditions that affect the aortic arch. The main benefit of a beveled aortic hemiarch replacement is that it ...

There are two primary diseases that can occur with the aortic valve: aortic stenosis and aortic insufficiency (also known as aortic regurgitation). Learn to understand and recognize the causes, ...

TAVIPILOT Soft is said to be a ‘world-first’ provision for real-time surgical guidance during TAVI and TAVR procedures.

Transcatheter aortic valve implantation (TAVI) is now an established treatment option for elderly patients with severe ...

monitoring and aortic valve replacement only when symptoms developed, or aortic valve replacement. For patients with asymptomatic, severe AS, the EARLY TAVR trial demonstrated that a strategy of ...

MiRus announced new early feasibility study results supporting the use of its Siegel transcatheter aortic valve replacement ...

Overview of Prosthetic Heart Valve MarketThe Global Prosthetic Heart Valve Market is valued at USD 8.74 Billion in 2024 and ...

A transcatheter aortic valve replacement system designed to treat aortic regurgitation exceeded its safety and performance goals. A randomized controlled trial comparing TAVR with surgery is planned.

IRVINE, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer and manufacturer of the TrilogyTM Transcatheter Heart Valve (THV) System, today announced that patient ...